Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2011-10-03 09:57:32 |
Versijas komentārs | |
Teksts |
The original preparation Mildronate® GX of “Grindeks” has received the prestigious award and nomination “The Cardiological Medication of the Year” in the awarding ceremony of the contest for pharmaceutical professionals “Panacea – 2011” in Ukraine. The Victory was ensured by high sales results in the Ukrainian market, as well as the effectiveness of the medication, proven in research and clinical practice. In the competition “Panacea – 2011”, which takes place in Ukraine for 12 years in a row, were selected and awarded the best, most professional pharmaceutical players. With this contest organizers wish to thank the pharmacy networks, medication wholesalers, pharmaceutical companies, who make a major contribution to the Ukrainian pharmaceutical industry and health care development.
Ukraine, home to more than 45 million inhabitants, is one of the strategic markets of “Grindeks”. Green registration process, medication marketing and promotion in Ukraine are provided by both the representative office of “Grindeks”, and partners, establishing a solid collaboration with the major medication wholesalers. In 2010, the turnover of “Grindeks” in Ukraine amounted to 10.2 million lats (the Group’s total turnover last year was 65.1 million lats).
Through the years Mildronate® has been the most important original product of “Grindeks”. However the company, expanding the range of medications and increasing sales of other medications in the last three years has reduced Mildronate® share in the turnover from 72% to 51%.
“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently “Grindeks” produces 16 active pharmaceutical ingredients. Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded “Grindeks” as the most export potential company of Latvia. During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years. JSC “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”. Major shareholders of JSC „Grindeks” are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “Skandinaviska Enskilda Banken” – 12.42%, “AB.LV Private Equity fund 2010” – 11.38%, “Swedbank” AS Clients Account – 6.87%. Further information on the company – www.grindeks.lv
Laila Kļaviņa |
Pielikumi |
|